Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question
K Sweet, J Pinilla-Ibarz - Critical Reviews in Oncology/Hematology, 2016 - Elsevier
Response to frontline BCR-ABL1-targeted tyrosine kinase inhibitor (TKI) therapy is
associated with an improved prognosis for patients with chronic myeloid leukemia (CML) …
associated with an improved prognosis for patients with chronic myeloid leukemia (CML) …
Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase
LP Akard, D Bixby - Leukemia & lymphoma, 2016 - Taylor & Francis
Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are available for the treatment of chronic
myeloid leukemia in chronic phase (CML-CP), and several baseline and on-treatment …
myeloid leukemia in chronic phase (CML-CP), and several baseline and on-treatment …
[HTML][HTML] Impact of molecular response at specific timepoints in patients with newly diagnosed chronic myeloid leukemia treated with second generation tyrosine kinase …
K Sasaki, HM Kantarjian, GC Issa, G Garcia-Manero… - Blood, 2020 - Elsevier
Background: Tyrosine kinase inhibitors (TKI) improve survival in patients with chronic
myeloid leukemia in chronic phase (CML-CP), who meet molecular milestones at specific …
myeloid leukemia in chronic phase (CML-CP), who meet molecular milestones at specific …
When to stop TKIs in patients with chronic myeloid leukemia and how to follow them subsequently
N Cerveira, S Bizarro, MR Teixeira, JM Mariz - Current Treatment Options …, 2021 - Springer
Opinion statement ABL1 tyrosine kinase inhibitors (TKI) have dramatically improved the
outcome for CML (chronic myeloid leukemia) patients. When TKI therapy is addressed …
outcome for CML (chronic myeloid leukemia) patients. When TKI therapy is addressed …
[HTML][HTML] The Target UK study: Real-world evidence of molecular response to tyrosine kinase inhibitors supports European LeukemiaNet 2013 recommendations for …
D Milojkovic, RE Clark, JL Byrne, BJP Huntly… - Blood, 2017 - Elsevier
Introduction: Several recent studies have shown the speed and depth of response to
tyrosine kinase inhibitor (TKI) treatment to be an important indicator of patient outcomes in …
tyrosine kinase inhibitor (TKI) treatment to be an important indicator of patient outcomes in …
Surrogate markers for treatment-free remission in patients with chronic myeloid leukemia
H Ureshino, K Kamachi, S Kimura - Clinical Lymphoma Myeloma and …, 2020 - Elsevier
BCR-ABL1 tyrosine kinase inhibitors (TKIs) improve long-term survival of patients with
chronic-phase (CP) chronic myeloid leukemia (CML). Recently, the treatment goal for …
chronic-phase (CP) chronic myeloid leukemia (CML). Recently, the treatment goal for …
Therapy in patients with chronic myeloid leukemia outside of clinical trials: results of the German CML-registry (CML-VI)
K Kohlbrenner, N Galuschek, A Fabarius, M Reiser… - Blood, 2022 - ashpublications.org
Introduction: Tyrosine kinase inhibitors (TKI) have significantly improved treatment outcomes
for patients with newly diagnosed chronic myelogenous leukemia (CML) in chronic phase …
for patients with newly diagnosed chronic myelogenous leukemia (CML) in chronic phase …
Which tyrosine kinase inhibitors should be selected as the first-line treatment for chronic myelogenous leukemia in chronic phase?
T Ono - Cancers, 2021 - mdpi.com
Simple Summary This review discusses the optimal selection of BCR-ABL1 tyrosine kinase
inhibitors (TKIs) as the first-line treatment for newly diagnosed chronic myelogenous …
inhibitors (TKIs) as the first-line treatment for newly diagnosed chronic myelogenous …
Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK …
Management of chronic myeloid leukaemia (CML) has recently undergone dramatic
changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; …
changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; …
First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI
G Saglio, E Jabbour - Leukemia & lymphoma, 2018 - Taylor & Francis
Patients diagnosed with chronic myeloid leukemia (CML) and treated with BCR-ABL1
tyrosine kinase inhibitors (TKIs) have long life spans. Selection of an appropriate first-line …
tyrosine kinase inhibitors (TKIs) have long life spans. Selection of an appropriate first-line …